 |
|
Cyclooxygenase Inhibitors for Skin Cancer Prevention
Are They Beneficial Enough?
Arch Dermatol. 2002;138:823-824.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
IN THIS issue of the ARCHIVES, Orengo et al1
confirm and extend recent exciting work in the field of skin cancer prevention.
In their study, hairless mice fed therapeutic doses of the selective cyclooxygenase
(COX) inhibitor celecoxib had dramatically reduced numbers of UV-B–induced
tumors. The data also show a trend toward longer latency before the appearance
of the tumors. This work, together with that of Pentland et al2
and Fischer et al,3 extends to skin observations
on the chemopreventive activity of COX-2 inhibitors. This class of drugs and
their parent compounds, the nonsteroidal anti-inflammatory drugs (NSAIDs),
have already been shown to be effective in reducing the incidence of breast
and colon cancer in humans in addition to other benefits such as reducing
the incidence of repeat myocardial infarction and decreasing the risk of Alzheimer
disease.4-8
The fact that NSAIDs are known to be so efficacious in preventing other human
tumors . . . [Full Text of this Article]
RELATED ARTICLE
Celecoxib, a Cyclooxygenase 2 Inhibitor as a Potential Chemopreventive to UV-Induced Skin Cancer: A Study in the Hairless Mouse Model
Ida F. Orengo, Janette Gerguis, Rhea Phillips, Adrian Guevara, Alan T. Lewis, and Homer S. Black
Arch Dermatol. 2002;138(6):751-755.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
T-oligo Treatment Decreases Constitutive and UVB-induced COX-2 Levels through p53- and NF{kappa}B-dependent Repression of the COX-2 Promoter
Marwaha et al.
J. Biol. Chem. 2005;280:32379-32388.
ABSTRACT
| FULL TEXT
Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice
Fischer et al.
Carcinogenesis 2003;24:945-952.
ABSTRACT
| FULL TEXT
|
